|
GB587992A
(en)
|
1944-12-11 |
1947-05-12 |
Charles William Scaife |
Improvements in and relating to the production of organic nitrogen compounds
|
|
US3578687A
(en)
*
|
1968-01-30 |
1971-05-11 |
Texaco Inc |
Process for producing 4-nitroalkanoic acids
|
|
US3819561A
(en)
*
|
1970-10-23 |
1974-06-25 |
Aerojet General Co |
Wetting agents for non-aqueous dispersions
|
|
JPS5313608B2
(enExample)
*
|
1972-06-16 |
1978-05-11 |
|
|
|
JPS5318013B2
(enExample)
|
1973-03-19 |
1978-06-13 |
|
|
|
US4599430A
(en)
|
1981-12-21 |
1986-07-08 |
The Standard Oil Company |
Nitrogenation of hydrocarbons, including the production of maleimide
|
|
JPS62132804A
(ja)
|
1985-12-05 |
1987-06-16 |
Aguro Kanesho Kk |
植物生長調節剤
|
|
US5412137A
(en)
|
1993-06-07 |
1995-05-02 |
Sandoz Ltd. |
Process for preparing phosphinyloxy propanaminium inner salt derivatives
|
|
US6074642A
(en)
*
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
CN1088058C
(zh)
|
1994-10-13 |
2002-07-24 |
肽技术有限公司 |
经修饰的多不饱和脂肪酸
|
|
US5741211A
(en)
|
1995-10-26 |
1998-04-21 |
Medtronic, Inc. |
System and method for continuous monitoring of diabetes-related blood constituents
|
|
GB9618420D0
(en)
|
1996-09-04 |
1996-10-16 |
Scotia Holdings Plc |
Fatty acid treatment
|
|
US6187747B1
(en)
|
1997-09-08 |
2001-02-13 |
Panacea Biotech Limited |
Pharmaceutical composition comprising cyclosporin
|
|
KR100569319B1
(ko)
|
1997-10-30 |
2006-04-07 |
모리시타 진탄 가부시키가이샤 |
불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
|
|
AU5565599A
(en)
|
1998-08-14 |
2000-03-06 |
Dante J. Marciani |
Chemically modified saponins and the use thereof as adjuvants
|
|
CN1329359C
(zh)
|
1999-04-01 |
2007-08-01 |
埃斯佩里安医疗公司 |
醚化合物,及其组合物和用途
|
|
AU5319499A
(en)
|
1999-07-22 |
2001-02-13 |
Ivan L. Cameron |
Fatty acids to minimize cancer therapy side effects
|
|
SE9903028D0
(sv)
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
|
AUPQ291499A0
(en)
*
|
1999-09-17 |
1999-10-07 |
Women's And Children's Hospital Adelaide |
Novel nitro and sulphur containing compounds
|
|
US6346231B1
(en)
|
1999-10-06 |
2002-02-12 |
Joar Opheim |
Flavored gelatin capsule and method of manufacture
|
|
US20010037598A1
(en)
*
|
1999-12-14 |
2001-11-08 |
Suppes Galen J. |
Process for producing cetane improvers from triglycerides
|
|
IL151299A0
(en)
|
2000-02-16 |
2003-04-10 |
Brigham & Womens Hospital |
Aspirin-triggered lipid mediators
|
|
AR030416A1
(es)
*
|
2000-04-13 |
2003-08-20 |
Pharmacia Corp |
COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
|
|
AR032318A1
(es)
*
|
2000-04-13 |
2003-11-05 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
|
|
AR034120A1
(es)
*
|
2000-04-13 |
2004-02-04 |
Pharmacia Corp |
Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
|
|
DK1294658T3
(da)
|
2000-06-28 |
2005-06-27 |
Zambon Spa |
Fremgangsmåde til fremstilling af nitroalkener
|
|
AR031129A1
(es)
*
|
2000-09-15 |
2003-09-10 |
Pharmacia Corp |
Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
|
|
CA2444463C
(en)
|
2001-04-18 |
2012-03-20 |
Prometic Biosciences Inc. |
Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
|
|
US7105556B2
(en)
|
2001-05-30 |
2006-09-12 |
Bristol-Myers Squibb Company |
Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
|
|
JPWO2002102364A1
(ja)
|
2001-06-18 |
2004-09-30 |
山田 幸子 |
ＰＰＡＲγ作動性医薬組成物
|
|
AU2002331618B2
(en)
|
2001-08-17 |
2007-11-01 |
University Of Pittsburgh |
Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
|
|
GB0123961D0
(en)
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
|
WO2003039533A1
(en)
|
2001-11-06 |
2003-05-15 |
The Brigham And Women's Hospital, Inc. |
Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
|
|
US7759395B2
(en)
|
2002-08-12 |
2010-07-20 |
The Brigham And Women's Hospital, Inc. |
Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
|
|
AU2003258909B2
(en)
|
2002-08-20 |
2010-07-08 |
Philera New Zealand Limited |
Dosage forms and related therapies
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
US7166575B2
(en)
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
WO2005016864A1
(en)
|
2003-07-29 |
2005-02-24 |
The Arizona Disease Control Research Commission |
Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
|
|
US20050136103A1
(en)
|
2003-09-17 |
2005-06-23 |
Ben-Sasson Shmuel A. |
Compositions capable of facilitating penetration across a biological barrier
|
|
AU2005209331A1
(en)
|
2004-01-30 |
2005-08-11 |
Peplin Biolipids Pty Ltd |
Therapeutic and carrier molecules
|
|
US20050232981A1
(en)
|
2004-04-15 |
2005-10-20 |
Ben-Sasson Shmuel A |
Compositions capable of facilitating penetration across a biological barrier
|
|
US7776916B2
(en)
*
|
2004-04-28 |
2010-08-17 |
The Uab Research Foundation |
Nitrated lipids and methods of making and using thereof
|
|
WO2006014673A2
(en)
|
2004-07-19 |
2006-02-09 |
Nobex Corporation |
Insulin-oligomer conjugates, formulations and uses thereof
|
|
WO2006011397A1
(ja)
|
2004-07-27 |
2006-02-02 |
Kowa Company., Ltd. |
糖尿病の予防または治療のための薬剤
|
|
KR20070090928A
(ko)
|
2004-11-19 |
2007-09-06 |
마텍 바이오싸이언스스 코포레이션 |
장쇄 다가불포화 지방산으로부터의 옥시리핀, 및 이의 제조방법 및 사용 방법
|
|
WO2006086727A2
(en)
|
2005-02-09 |
2006-08-17 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
US9274129B2
(en)
|
2006-05-31 |
2016-03-01 |
Lpath, Inc. |
Methods and reagents for detecting bioactive lipids
|
|
US20090264483A1
(en)
|
2006-07-14 |
2009-10-22 |
Cedars-Sinai Medical Center |
METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
|
|
WO2008011085A1
(en)
|
2006-07-19 |
2008-01-24 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for the treatment of mucositis
|
|
US20110190389A1
(en)
|
2007-02-20 |
2011-08-04 |
Linda Arterburn |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
|
US8324277B2
(en)
|
2007-08-01 |
2012-12-04 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Nitrated-fatty acids modulation of type II diabetes
|
|
CA2699483A1
(en)
|
2007-09-14 |
2009-03-26 |
Resolvyx Pharmaceuticals, Inc. |
Compositions and methods for modulating immune function
|
|
US20110092594A1
(en)
|
2008-04-18 |
2011-04-21 |
Tianxin Yang |
Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
|
|
CN102083787A
(zh)
|
2008-05-01 |
2011-06-01 |
康普雷克萨公司 |
乙烯基取代的脂肪酸
|
|
WO2009149496A1
(en)
|
2008-06-10 |
2009-12-17 |
Central Northern Adelaide Health Service |
Treatment of diabetes and complications thereof and related disorders
|
|
WO2009155439A2
(en)
|
2008-06-19 |
2009-12-23 |
University Of Utah Research Foundation |
Use of nitrated lipids for treatment of side effects of toxic medical therapies
|
|
WO2010042877A1
(en)
|
2008-10-09 |
2010-04-15 |
Tekmira Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
US8933255B2
(en)
|
2008-12-31 |
2015-01-13 |
Nitromega Corp. |
Nutraceuticals containing nitro fatty acids
|
|
US8937194B2
(en)
|
2008-12-31 |
2015-01-20 |
Nitromega Corp. |
Topical compositions containing nitro fatty acids
|
|
US20100286272A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
|
|
US20100286271A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Nitro-alkyl Compound Compositions
|
|
US20100286257A1
(en)
|
2009-05-08 |
2010-11-11 |
Perricone Nicholas V |
Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
|
|
EP2459510A4
(en)
|
2009-07-29 |
2013-08-07 |
Phenomenome Discoveries Inc |
HYDROXIDE-FATTY ACID COMPOSITIONS AND USES THEREOF FOR ILLNESS TREATMENT AND DIAGNOSIS
|
|
JP2013500966A
(ja)
|
2009-07-31 |
2013-01-10 |
ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション |
抗炎症剤としての脂肪酸
|
|
US8686167B2
(en)
|
2009-10-02 |
2014-04-01 |
Complexa, Inc. |
Heteroatom containing substituted fatty acids
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
US8563609B2
(en)
|
2010-05-13 |
2013-10-22 |
Nitromega Corp. |
Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
|
|
EP2590643A4
(en)
|
2010-06-28 |
2014-01-01 |
Complexa Inc |
MEDICINAL PRODUCT MADE FROM SEVERAL INGREDIENTS FOR THE TREATMENT OF DIABETES
|
|
WO2013028501A1
(en)
|
2011-08-19 |
2013-02-28 |
The University Of Utah Research Foundation |
Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
|
|
US9271952B2
(en)
|
2011-10-11 |
2016-03-01 |
Complexa, Inc. |
Compositions and methods for treating nephropathy
|
|
IL258476B2
(en)
*
|
2015-10-02 |
2023-04-01 |
Complexa Inc |
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
|